Cell-based therapies for ARDS - Where are we now?

Gerard F Curley, Cecilia M O'Kane, Daniel F McAuley, Michael A Matthay, John G Laffey

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
39 Downloads (Pure)


There is considerable interest in the potential for cell-based therapies, particularly mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory distress syndrome (ARDS). MSCs exert effects via diverse mechanisms including reducing excessive inflammation by modulating neutrophil, macrophage and T-cell function, decreasing pulmonary permeability and lung edema, and promoting tissue repair. Clinical studies indicate that MSCs are safe and well tolerated, with promising therapeutic benefits in specific clinical settings, leading to regulatory approvals of MSCs for specific indications in some countries.

This perspective reassesses the therapeutic potential of MSC-based therapies for ARDS given insights from recent cell therapy trials in both COVID-19 and in ‘classic’ ARDS, and discusses studies in graft-vs.-host disease, one of the few licensed indications for MSC therapies. We identify important unknowns in the current literature, address challenges to clinical translation, and propose an approach to facilitate assessment of the therapeutic promise of MSC-based therapies for ARDS.
Original languageEnglish
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Early online date07 Feb 2024
Publication statusEarly online date - 07 Feb 2024


  • Cell Therapy
  • Mesenchymal Stromal Cells
  • ARDS Therapies
  • Mesenchymal Stem Cells


Dive into the research topics of 'Cell-based therapies for ARDS - Where are we now?'. Together they form a unique fingerprint.

Cite this